HR Execs on the Move

The Boston Home Inc.

www.thebostonhome.org

 
The Boston Home Inc. is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Boston, MA. To find more information about The Boston Home Inc., please visit www.thebostonhome.org
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

CAnCare of Houston

CAnCare of Houston is a Houston, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neich Medical Co.

Neich Medical Co. is a Dublin, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Besafemeds

Besafemeds takes today`s technology and applies it to healthcare to deliver a discreet treatment option for STDs. We store no identifiable data on our users. Once a determination is made that a prescription is needed and subsequently transmitted to the pharmacy of your choice, all identifiable data is purged from the system. Besafemeds is staffed by physicians and nurse practitioners following standard treatment guidelines for the two most common STDs (gonorrhea and chlamydia). In an ideal world, testing should occur before treatment. However, besafemeds is here for those who need or want a discreet and quick STD treatment option.

Gateway Community Services Medical Clinic

Gateway Community Services Medical Clinic is a East Lansing, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.